{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+%2F+Recurrent+Germ+Cell+Tumors",
    "query": {
      "condition": "Relapsed / Recurrent Germ Cell Tumors"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 195,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+%2F+Recurrent+Germ+Cell+Tumors&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T10:18:21.678Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01962896",
      "title": "A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed / Recurrent Germ Cell Tumors"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theodore Laetsch",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Months to 50 Years"
      },
      "enrollment_count": 4,
      "start_date": "2014-01-08",
      "completion_date": "2018-01-27",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-06-07T10:18:21.678Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Memphis, Tennessee • Dallas, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962896"
    },
    {
      "nct_id": "NCT01112527",
      "title": "PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "GBM",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "PF-00299804",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2010-04",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2018-08-16",
      "last_synced_at": "2026-06-07T10:18:21.678Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • Cleveland, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01112527"
    },
    {
      "nct_id": "NCT00898612",
      "title": "Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2008-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-03-10",
      "last_synced_at": "2026-06-07T10:18:21.678Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00898612"
    },
    {
      "nct_id": "NCT00049465",
      "title": "Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "fatigue assessment and management",
          "type": "PROCEDURE"
        },
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "psychosocial assessment and care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-09-21",
      "last_synced_at": "2026-06-07T10:18:21.678Z",
      "location_count": 9,
      "location_summary": "Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049465"
    },
    {
      "nct_id": "NCT03458728",
      "title": "Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Solid Tumors or Lymphoma in Children",
        "Neuroblastoma",
        "Osteosarcoma",
        "Rhabdomyosarcoma",
        "Ewing Sarcoma"
      ],
      "interventions": [
        {
          "name": "Copanlisib (BAY806946)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 31,
      "start_date": "2018-04-30",
      "completion_date": "2023-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-12-04",
      "last_synced_at": "2026-06-07T10:18:21.678Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Orange, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03458728"
    },
    {
      "nct_id": "NCT00363272",
      "title": "Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Burkitt Lymphoma",
        "Childhood Central Nervous System Germ Cell Tumor",
        "Childhood Choroid Plexus Tumor",
        "Childhood Craniopharyngioma",
        "Childhood Grade I Meningioma",
        "Childhood Grade II Meningioma",
        "Childhood Grade III Meningioma",
        "Childhood High-grade Cerebral Astrocytoma",
        "Childhood Infratentorial Ependymoma",
        "Childhood Low-grade Cerebral Astrocytoma",
        "Childhood Spinal Cord Neoplasm",
        "Childhood Supratentorial Ependymoma",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Brain Tumor",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Grade III Lymphomatoid Granulomatosis",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Visual Pathway and Hypothalamic Glioma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ispinesib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-06-07T10:18:21.678Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00363272"
    },
    {
      "nct_id": "NCT00084695",
      "title": "Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Langerhans Cell Histiocytosis",
        "Fanconi Anemia",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Neuroblastoma",
        "Sarcoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 25,
      "start_date": "2003-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-06-07T10:18:21.678Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00084695"
    },
    {
      "nct_id": "NCT00107237",
      "title": "AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "AEE788",
          "type": "DRUG"
        },
        {
          "name": "everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2003-10",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-12",
      "last_synced_at": "2026-06-07T10:18:21.678Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Durham, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00107237"
    },
    {
      "nct_id": "NCT00450827",
      "title": "Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "iodine I 131 monoclonal antibody 3F8",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 25,
      "start_date": "2006-08",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2015-09-28",
      "last_synced_at": "2026-06-07T10:18:21.678Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00450827"
    },
    {
      "nct_id": "NCT00060372",
      "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",
        "Childhood Myelodysplastic Syndromes",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Disseminated Neuroblastoma",
        "Malignant Neoplasm",
        "Ovarian Choriocarcinoma",
        "Ovarian Embryonal Carcinoma",
        "Ovarian Immature Teratoma",
        "Ovarian Mature Teratoma",
        "Ovarian Mixed Germ Cell Tumor",
        "Ovarian Monodermal and Highly Specialized Teratoma",
        "Ovarian Polyembryoma",
        "Ovarian Yolk Sac Tumor",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Neuroblastoma",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Ovarian Germ Cell Tumor",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Multiple Myeloma",
        "Relapsing Chronic Myelogenous Leukemia",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage II Ovarian Epithelial Cancer",
        "Stage III Malignant Testicular Germ Cell Tumor",
        "Stage III Multiple Myeloma",
        "Stage III Ovarian Epithelial Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Testicular Choriocarcinoma",
        "Testicular Choriocarcinoma and Embryonal Carcinoma",
        "Testicular Choriocarcinoma and Seminoma",
        "Testicular Choriocarcinoma and Teratoma",
        "Testicular Choriocarcinoma and Yolk Sac Tumor",
        "Testicular Embryonal Carcinoma",
        "Testicular Embryonal Carcinoma and Seminoma",
        "Testicular Embryonal Carcinoma and Teratoma",
        "Testicular Embryonal Carcinoma and Teratoma With Seminoma",
        "Testicular Embryonal Carcinoma and Yolk Sac Tumor",
        "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma",
        "Testicular Teratoma",
        "Testicular Yolk Sac Tumor",
        "Testicular Yolk Sac Tumor and Teratoma",
        "Testicular Yolk Sac Tumor and Teratoma With Seminoma"
      ],
      "interventions": [
        {
          "name": "ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2003-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-03-27",
      "last_synced_at": "2026-06-07T10:18:21.678Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00060372"
    }
  ]
}